Indivior PLC (LON:INDV)‘s stock had its “buy” rating reissued by equities research analysts at Numis Securities Ltd in a note issued to investors on Friday. They currently have a GBX 470 ($6.07) price target on the specialty pharmaceutical company’s stock. Numis Securities Ltd’s price target would indicate a potential upside of 59.05% from the company’s current price.

A number of other brokerages also recently issued reports on INDV. Stifel Nicolaus reiterated a “buy” rating and set a GBX 400 ($5.17) price target on shares of Indivior PLC in a research report on Friday. Citigroup Inc. reissued a “neutral” rating and set a GBX 280 ($3.62) target price on shares of Indivior PLC in a report on Tuesday, September 5th. Royal Bank Of Canada raised Indivior PLC to an “outperform” rating and increased their target price for the company from GBX 390 ($5.04) to GBX 470 ($6.07) in a report on Friday, July 28th. Finally, Jefferies Group LLC cut their price target on Indivior PLC from GBX 540 ($6.97) to GBX 358 ($4.62) and set a “buy” rating for the company in a report on Friday, September 8th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Indivior PLC currently has a consensus rating of “Buy” and a consensus target price of GBX 395.50 ($5.11).

Shares of Indivior PLC (LON:INDV) traded up 1.56% on Friday, reaching GBX 300.10. The company’s stock had a trading volume of 1,844,107 shares. The firm has a 50 day moving average price of GBX 371.14 and a 200-day moving average price of GBX 336.83. Indivior PLC has a 12-month low of GBX 246.50 and a 12-month high of GBX 421.50. The stock’s market cap is GBX 2.16 billion.

TRADEMARK VIOLATION WARNING: “Indivior PLC’s (INDV) Buy Rating Reiterated at Numis Securities Ltd” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/15/indivior-plcs-indv-buy-rating-reiterated-at-numis-securities-ltd.html.

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior PLC (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.